CLL Biobank: Mechansims in drug resistance in chronic lymphocytic leukemia, Canada

Certification Status: Approved

Registration Status: Completed

Objective: Chronic lymphocytic leukemia (CLL) remain an incurable leukemia even with targeted therapies extending remissions and overall survival in CLL patients. Eventually the CLL cells become resistant to these targeted therapies requiring new approaches to treat this disease. In this study, we will collect blood samples from CLL patients before they receive treatment, during treatment and at time of relapse. We will evaluate mechanisms of drug resistance in the cells such as reactive oxygen species levels, autophagy flux and Bcl-2 family members following targeted treatments with Ibrutinib or venetoclax. This will give insight into the mechanism of drug resistance and strategies to overcome this resistance.

Registered Biobank Name	CLL Biobank: Mechansims in drug resistance in chronic lymphocytic leukemia
Biobank Leader	Spencer B Gibson
Country	Canada
Email for biobank inquiries	sgibson2@ualberta.ca
Principal Investigator	Spencer Gibson
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Oligo - Collection aimed at supporting several research projects, a research group or a research consortium

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).